New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.

[1]  H. Bergmeyer.  Methods of Enzymatic Analysis , 2019 .

[2]  Andrew Henwood,et al.  Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. , 2003, Journal of medicinal chemistry.

[3]  C. Gleiter,et al.  Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. , 2002, European journal of medical research.

[4]  J. Cartledge,et al.  TADALAFIL (CIALIS™) FOR MEN WITH ERECTILE DYSFUNCTION , 2002, International journal of clinical practice.

[5]  H. Porst.  IC351 (tadalafil, Cialis): update on clinical experience , 2002, International Journal of Impotence Research.

[6]  V. D. Piaz,et al.  Synthesis and Evaluation of Some Pyrazolo[3,4-d]pyridazinones and Analogues as PDE 5 Inhibitors Potentially Useful as Peripheral Vasodilator Agents , 2002, Journal of enzyme inhibition and medicinal chemistry.

[7]  M. Giovannoni,et al.  Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. , 2000, European journal of medicinal chemistry.

[8]  G. Brock.  Sildenafil citrate (Viagra). , 2000, Drugs of today.

[9]  Aytaç,et al.  The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences , 1999, BJU international.

[10]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[11]  V. D. Piaz,et al.  Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies , 1998 .

[12]  Truss Mc,et al.  Phosphodiesterase inhibitors in the treatment of erectile dysfunction. , 1998 .

[13]  M. Giovannoni,et al.  Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. , 1997, Journal of medicinal chemistry.

[14]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[15]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[16]  J. Beavo,et al.  Multiple cyclic nucleotide phosphodiesterases. , 1994, Molecular pharmacology.

[17]  J. Beleta,et al.  Studies on the cardiac actions of flosequinan in vitro , 1992, British journal of pharmacology.

[18]  S. Pinzauti,et al.  Condensation of some 3‐methylisoxazolo[3,4‐d]pyridazin‐7(6H)ones with aromatic aldehydes , 1976 .

[19]  D. Juilfs,et al.  Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). , 1999, Reviews of physiology, biochemistry and pharmacology.

[20]  J C Gingell,et al.  The epidemiology and pathophysiology of erectile dysfunction. , 1999, The Journal of urology.

[21]  M. Czarniecki,et al.  Chapter 7. Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy , 1996 .

[22]  K. Andersson,et al.  Physiology of penile erection. , 1995, Physiological reviews.

[23]  V. D. Piaz,et al.  Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-7(8H)-one: a new heterocyclic ring system from isoxazolopyridazinones , 1986 .